iMedicor (OTCBB: VMCI) and Transgenomic (OTCBB:TBIO) today announced that they have signed an agreement to develop an educational marketing program for NuroPro, Transgenomic’s diagnostic tests for Alzheimer’s and Parkinson’s disease. The alerts-based Internet program will target neurologists, gerontologists and primary care physicians to announce the commercial launch of Transgenomic’s NuroPro assays for these devastating neurological diseases.
Through its HIPAA-compliant information transfer and communications portal, iMedicor’s proprietary Alert system will provide a unique, in-depth targeted program that places client messages in the hands of specific physicians and their staff at the point of care. Programs like the one announced today comply with the Obama Administration’s goals of improving healthcare and reducing cost associated with the early detection of debilitating, chronic diseases like Alzheimer’s and Parkinson’s disease.
“iMedicor’s ability to deliver targeted access to very specific physician audiences will significantly increase our client’s marketing ROI and we look forward to working with Transgenomic to help them maximize their educational marketing efforts in a cost effective, non-intrusive manner,” said Fred Zolla, CEO of Vemics iMedicor. “This program also gives us an opportunity to showcase iMedicor’s effective and innovative platform.”